Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOLTO: Multi-maintenance Olaparib in BRCAm Ovarian Cancer
NCT02855697Phase 1Completed
- Sponsor
- The Christie
- Start
- May 2017
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olaparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by The Christie. Primary endpoint: Feasibility of administering a second course of maintenance olaparib at 6 months. Started May 2017; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02855697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02855697.